348 related articles for article (PubMed ID: 22239286)
1. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR; Wang Y
J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
[TBL] [Abstract][Full Text] [Related]
2. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
3. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
4. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
5. Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation.
Chen J; Zhang S; Liu X; Zhang Q
J Mol Model; 2010 Mar; 16(3):459-68. PubMed ID: 19629548
[TBL] [Abstract][Full Text] [Related]
6. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
7. Computational Studies of a Mechanism for Binding and Drug Resistance in the Wild Type and Four Mutations of HIV-1 Protease with a GRL-0519 Inhibitor.
Hu G; Ma A; Dou X; Zhao L; Wang J
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240358
[TBL] [Abstract][Full Text] [Related]
8. Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2012 Sep; 38():430-45. PubMed ID: 23142620
[TBL] [Abstract][Full Text] [Related]
9. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
Tzoupis H; Leonis G; Avramopoulos A; Mavromoustakos T; Papadopoulos MG
J Phys Chem B; 2014 Aug; 118(32):9538-52. PubMed ID: 25036111
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
[TBL] [Abstract][Full Text] [Related]
11. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
12. Computational studies of darunavir into HIV-1 protease and DMPC bilayer: necessary conditions for effective binding and the role of the flaps.
Leonis G; Czyżnikowska Ż; Megariotis G; Reis H; Papadopoulos MG
J Chem Inf Model; 2012 Jun; 52(6):1542-58. PubMed ID: 22587384
[TBL] [Abstract][Full Text] [Related]
13. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
14. Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114.
Kovalevsky AY; Liu F; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2006 Oct; 363(1):161-73. PubMed ID: 16962136
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
Kovalevsky AY; Tie Y; Liu F; Boross PI; Wang YF; Leshchenko S; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2006 Feb; 49(4):1379-87. PubMed ID: 16480273
[TBL] [Abstract][Full Text] [Related]
16. Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations.
Hu GD; Zhu T; Zhang SL; Wang D; Zhang QG
Eur J Med Chem; 2010 Jan; 45(1):227-35. PubMed ID: 19910081
[TBL] [Abstract][Full Text] [Related]
17. Revealing the binding and drug resistance mechanism of amprenavir, indinavir, ritonavir, and nelfinavir complexed with HIV-1 protease due to double mutations G48T/L89M by molecular dynamics simulations and free energy analyses.
Wang RG; Zhang HX; Zheng QC
Phys Chem Chem Phys; 2020 Feb; 22(8):4464-4480. PubMed ID: 32057044
[TBL] [Abstract][Full Text] [Related]
18. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
19. Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir.
Yu Y; Wang J; Shao Q; Shi J; Zhu W
Sci Rep; 2015 May; 5():10517. PubMed ID: 26012849
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the resilience of Darunavir (TMC114) resistance major flap mutations of HIV-1 protease.
Purohit R; Sethumadhavan R
Interdiscip Sci; 2009 Dec; 1(4):320-8. PubMed ID: 20640812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
